English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant

Soucek, R., Thomas, D., Kelemen, K., Bikou, O., Seyler, C., Voss, F., et al. (2012). Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm, 9(2), 265-272. doi:10.1016/j.hrthm.2011.09.008.

Item is

Basic

show hide
Genre: Journal Article
Alternative Title : Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant

Files

show Files
hide Files
:
HeartRhythm_9_2012_265.pdf (Any fulltext), 731KB
 
File Permalink:
-
Name:
HeartRhythm_9_2012_265.pdf
Description:
-
OA-Status:
Visibility:
Restricted (Max Planck Institute for Medical Research, MHMF; )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show
hide
Description:
-
OA-Status:

Creators

show
hide
 Creators:
Soucek, Radim, Author
Thomas, Dierk, Author
Kelemen, Kamilla, Author
Bikou, Olympia, Author
Seyler, Claudia, Author
Voss, Frederik, Author
Becker, Rüdiger, Author
Koenen, Michael1, Author           
Katus, Hugo A., Author
Bauer, Alexander, Author
Affiliations:
1Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Max Planck Society, ou_1497704              

Content

show
hide
Free keywords: Atrial fibrillation; Gene Therapy; HERG; Ion channel; Rhythm control
 Abstract: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Gene therapy−dependent modulation of atrial electrophysiology may provide a more specific alternative to pharmacological and ablative treatment strategies. Objective We hypothesized that genetic inactivation of atrial repolarizing ether−a−go−go−related gene (ERG) K+ currents using a dominant−negative mutant would provide rhythm control in AF. Methods Ten domestic swine underwent pacemaker implantation and were subjected to atrial burst pacing to induce persistent AF. Animals were then randomized to receive either AdCERG−G627S to suppress ERG/IKr currents or green fluorescent protein (AdGFP) as control. Adenoviruses were applied using a novel hybrid technique employing atrial virus injection followed by epicardial electroporation to increase transgene expression. Results In pigs treated with AdCERG−G627S, the onset of persistent AF was prevented (n = 2) or significantly delayed compared to AdGFP controls (12 ± 2.1 vs. 6.2 ± 1.3 days; P < .001) during 14 day follow−up. Effective refractory periods were prolonged in the AdCERG−G627S group compared to AdGFP animals (221.5 ± 4.7 ms vs. 197.0 ± 4.7 ms; P < .006). Impairment of left ventricular ejection fraction (LVEF) during AF was prevented by AdCERG−G627S application (LVEFCERG−G627S = 62.1 ± 4.0% vs. LVEFGFP = 30.3 ± 9.1%; P < .001). Conclusion Inhibition of ERG function using atrial AdCERG−G627S gene transfer suppresses or delays the onset of persistent AF by prolongation of atrial refractoriness in a porcine model. Targeted gene therapy represents an alternative to pharmacological or ablative treatment of AF

Details

show
hide
Language(s): eng - English
 Dates: 2011-06-022011-09-022011-09-092012-02-01
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Heart Rhythm
  Alternative Title : Heart Rhythm
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 9 (2) Sequence Number: - Start / End Page: 265 - 272 Identifier: -